Comparative CYB003 pre-clinical data
on the Company's deuterated psilocybin analog may have
wide-reaching implications for the treatment of Major Depressive
Disorder ("MDD") and Alcohol Use Disorder
("AUD") with less patient variability, faster
onset of action, shorter duration of effect and improved brain
penetration
TORONTO, Canada -- November 8, 2021 -- InvestorsHub
NewsWire -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"
or the "Company"), a biopharmaceutical company
focused on progressing "Psychedelics to TherapeuticsTM",
today announced positive CYB003 pre-clinical findings that
demonstrate multiple advantages for its newly developed novel
deuterated psilocybin analog over oral psilocybin for the treatment
of mental health.
"Multiple academic studies have shown that psilocybin may have
the potential to revolutionize mental healthcare, but few companies
have addressed the well-known limitations and side effects of oral
psilocybin. Cybin has always strived to develop safer and more
effective therapies for patients, which has guided our multiple
psilocybin programs: CYB001, CYB002, and CYB003," said Doug
Drysdale, Cybin's Chief Executive Officer.
Academic research performed at New York University and John
Hopkins University has indicated oral psilocybin to be efficacious
in the treatment of mental health disorders, especially MDD, but
with significant limitations, specifically: slow onset of action,
extended duration of effect, and a variability in response among
patients. The Company's CYB001 and CYB002 programs studied
proprietary formulations, while the Company's CYB003 program
explored proprietary analogs with the goal to retain the benefits
and address the challenges. Today the Company is pleased to
announce that its proprietary molecular advancements offer positive
benefits and address the challenges and limitations of oral
psilocybin.
In multi-species pre-clinical studies, the Company's deuterated
psilocybin analog from its CYB003 program demonstrates:
-
a 50% shorter time to onset when compared to oral psilocybin;
indicates potential for shorter duration of treatment, lower
inter-subject variability, better therapeutic control and safety,
leading to a better patient experience, with lower cost and
scalability; and
The deuterated psilocybin analog in CYB003 has the potential to
reduce time and resource burden on patients, providers and payers,
and possibly improving scalability and accessibility from the
following conclusions:
-
faster onset of action equates to less down time in the clinic
before effects begin;
-
half the duration of effect translates to shorter clinic days or
more patients per day;
-
more predictable dose effects create a safer and more effective
patient response;
-
lowered peripheral exposure diminishes the risk of nausea;
and
-
better brain penetration suggests lower overall dose needed to
achieve clinical efficacy.
"While we are all encouraged by the benefits of psilocybin, we
need to transparently and openly discuss its limitations if we are
to translate psychedelics to therapeutics for patients in need. The
majority of current clinical studies are based on psilocybin. We
have taken the necessary steps to potentially unlock the powerful
benefits of psychedelics and engineer a superior molecule as
demonstrated by the data. We are on a mission to make ethical, safe
scientific progress to advance the care and treatment of mental
health patients. Our goal has always been to be a leader in
creating the best therapy for patients, today we move one step
closer," said Doug Drysdale, Cybin's Chief Executive Officer.
The presentation showcasing the Company's data will be made
available on the Cybin website within 24 hours.
As a reminder, the Company welcomes all media and analysts that
are attending the Wonderland Conference in Miami to physically join
its presentation today at 8:30am EDT.
Physical address for attendees:
Physical event is for media attendees and analysts only. To
RSVP, please email info@cybin.com.
The Adrienne Arsht Center for the Performing
Arts
Next Generation Green Room
Arts of Miami-Dade County, Inc.
1300 Biscayne Blvd. Miami, FL 33132
The Company welcomes shareholders and the general public to
virtually join its presentation today at 8:30am EDT.
Virtual Webcast:
Virtual event is open to shareholders and the general
public.
Topic: Cybin Research & Development Press Conference
Location: Wonderland Conference, Miami, FL
Time: Nov 8, 2021 08:30 AM Eastern Time (US and Canada)
Join Zoom Meeting
https://imageav.zoom.us/j/82993672583?pwd=cW9zQi9Xc1BCbExpTGh5T09aS1hGUT09
One tap mobile
+13462487799,,82993672583#,,,,*730988# US
Dial by your location
Meeting ID: 829 9367 2583
Passcode: 730988
Find your local number: https://imageav.zoom.us/u/kWOoByjaK
About Cybin
Cybin is a leading ethical biopharmaceutical company, working
with a network of world-class partners and
internationally-recognized scientists, on a mission to create safe
and effective therapeutics for patients to address a multitude of
mental health issues. Headquartered in Canada and founded in 2019,
Cybin is operational in the USA, UK and Ireland. The Company is
focused on progressing Psychedelics to Therapeutics by engineering
proprietary drug discovery platforms, innovative drug delivery
systems, novel formulation approaches and treatment regimens for
mental health disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this press release constitute
forward-looking information. All statements other than statements
of historical fact contained in this press release, including,
without limitation, statements regarding Cybin's future, strategy,
plans, objectives, goals and targets, and any statements preceded
by, followed by or that include the words "believe", "expect",
"aim", "intend", "plan", "continue", "will", "may", "would",
"anticipate", "estimate", "forecast", "predict", "project", "seek",
"should" or similar expressions or the negative thereof, are
forward-looking statements. Forward-looking statements in this news
release include statements regarding the potential benefits of the
Company's multiple psilocybin program CYB001, CYB002, and CYB003,
the potential benefits of psilocybin, and the development of the
Company's proprietary drug discovery platforms, innovative drug
delivery systems, novel formulation approaches and treatment
regimens in order to advance the care and treatment of mental
health patients and to address a multitude of mental health
issues.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the COVID-19
pandemic on the Company's operations; fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; and the risk factors set out in the Company's
management's discussion and analysis for the period ended June 30,
2021 and the Company's listing statement dated November 9, 2020,
which are available under the Company's profile
on www.sedar.com and with the U.S. Securities
and Exchange Commission on EDGAR at www.sec.gov.
Although the forward-looking statements contained in this news
release are based upon what management of the Company believes, or
believed at the time, to be reasonable assumptions, the Company
cannot assure shareholders that actual results will be consistent
with such forward-looking statements, as there may be other factors
that cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC
stock exchange have approved or disapproved the contents of this
news release and are not responsible for the adequacy and accuracy
of the contents herein.
Contacts
Investor & Media Contacts:
Leah Gibson
Vice President Investor Relations
Cybin Inc.
leah@cybin.com
Tim Regan/Scott Eckstein
KCSA Strategic Communications
cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Cybin (AMEX:CYBN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cybin (AMEX:CYBN)
Historical Stock Chart
From Apr 2023 to Apr 2024